

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/09743 A1

- (51) International Patent Classification⁷: **A61K 38/48**, A61P 35/00
- (21) International Application Number: PCT/US01/22885
- (22) International Filing Date: 20 July 2001 (20.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/631,221 2 August 2000 (02.08.2000) US
- (71) Applicant (for all designated States except US): **ALLERGAN SALES, INC.** [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **DONOVAN, Stephen** [CA/US]; 27252 Calle Anejo, Capistrano Beach, CA 92624 (US).
- (74) Agents: **DONOVAN, Stephen et al.**; Allergan Sales, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/09743 A1

(54) Title: METHOD FOR TREATING A NEOPLASM

(57) Abstract: A method for treating a neoplasm by local administration of a botulinum toxin to the neoplasm to thereby reducing the size and/or a secretory activity of the neoplasm.

METHOD FOR TREATING A NEOPLASM

5

CROSS REFERENCE

10 This application is a continuation in part of application serial number 09/454,842, filed December 7, 1999.

BACKGROUND

15

The present invention relates to methods for treating neoplasms. In particular the present invention relates to methods for treating secretory neoplasms, both benign and cancerous, as well as hyperplastic chromaffin cells by local administration of a neurotoxin.

20

Adrenal Medulla

The adrenal or suprarenal glands are small, triangular-shaped structures located on top of the kidneys. Each adrenal gland comprises an adrenal cortex or outer portion and an adrenal medulla or inner portion. The cortex
25 surrounds and encloses the medulla.

The adrenal cortex secretes the hormones cortisol and aldosterone. Cortisol is produced during times of stress, regulates sugar usage, and is essential for maintenance of normal blood pressure. Aldosterone is one of
30 the main regulators of salt, potassium and water balance. If both adrenal

glands are removed cortisol and aldosterone replacement therapy is mandatory.

The adrenal medulla secretes the catecholamines adrenalin
5 (synonymously epinephrine) and noradrenalin (synonymously
norepinephrine). These hormones are important for the normal regulation
of a variety of bodily functions, including stress reaction, when they cause
an increase in blood pressure, the pumping ability of the heart, and the
level of blood sugar. Removal of the adrenal medulla results in little or no
10 hormonal deficiency because other glands in the body can compensate.
Contrarily, excessive catecholamine production can be life threatening.


In the normal adult male about 85% of total catecholamine made by the
adrenal medulla is adrenaline, with the remaining 15% being noradrenalin.
15 There is about 1.6 mg of catecholamine present per gram of medulla
tissue. Most of the noradrenalin found in blood and urine comes not from
the adrenal medulla but from postganglionic sympathetic nerve endings. If
the freshly sectioned adrenal gland is placed in fixatives that contain
potassium dichromate, the medulla turns brown and this is referred to as
20 the chromaffin reaction, so named to suggest the affinity of adrenal medulla
tissue for chromium salts. Hence, cells of the adrenal medulla are often
called chromaffin cells. Chromaffin cells also exists outside the adrenal
medulla, but usually secrete only noradrenalin, not adrenaline.

25 The adrenal medulla can be viewed as a sympathetic ganglion
innervated by preganglionic cholinergic nerve fibers. These nerve fibers
release acetylcholine which causes secretion of catecholamines (primarily
adrenaline) by a process of exocytosis from the chromaffin cells of the
adrenal medulla. The normal adrenal medulla is innervated by the
30 splanchnic nerve, a preganglionic, cholinergic branch of the sympathetic

nervous system. The activity of the adrenal medulla is almost entirely under such cholinergic nervous control.

5 Chromaffin Cell Tumors

Chromaffin cells (including the chromaffin cells of the adrenal medulla) and sympathetic ganglion cells have much in common as they are both derived from a common embryonic ancestor, the sympathagonium of the neural crest, as shown diagrammatically below. Examples of the types of neoplasms which can arise from each these cell types is shown in brackets. Each of the cell types shown can potentially secrete catecholamines.



25 While most chromaffin cell neoplasms occur in the adrenal medulla, ectopic and multiple location chromaffin cell tumors are known, occurring most commonly in children.

1. Paragangliomas

30 A paraganglia (synonymously, chromaffin body) can be found in the heart, near the aorta, in the kidney, liver, gonads, and other places and is

comprised of chromaffin cells which apparently originate from neural crest cells and which have migrated to a close association with autonomic nervous system ganglion cells. A paraganglioma is a neoplasm comprised of chromaffin cells derived from a paraganglia. A carotid body
5 paraganglioma is referred to as a carotid paraganglioma, while an adrenal medulla paraganglioma is called a pheochromocytoma or a chromaffinoma.

The carotid body is often observed as a round, reddish-brown to tan structure found in the adventitia of the common carotid artery. It can be
10 located on the posteromedial wall of the vessel at its bifurcation and is attached by ayer's ligament through which the feeding vessels run primarily from the external carotid. A normal carotid body measures 3-5 mm in diameter. Afferent innervation appears to be provided through the glossopharyngeal nerve (the ninth cranial nerve). The glossopharyngeal
15 nerve supplies motor fibers to the stylopharyngeus, parasympathetic secretomotor fibers to the parotid gland and sensory fibers to *inter alia* the tympanic cavity, interior surface of the soft palate and tonsils). Histologically, the carotid body includes Type I (chief) cells with copious cytoplasm and large round or oval nuclei. The cytoplasm contains dense
20 core granules that apparently store and release catecholamines. The normal carotid body is responsible for detecting changes in the composition of arterial blood.

Carotid paragangliomas are rare tumors overall but are the most
25 common form of head and neck paraganglioma. The treatment of choice for most carotid body paragangliomas is surgical excision. However, because of their location in close approximation to important vessels and nerves, there is a very real risk of morbidity(mainly cranial nerve X-XII deficits and vascular injuries) and mortality which is estimated as 3-9%.
30 Tumor size is important because those greater than 5 cm in diameter have

a markedly higher incidence of complications. Perioperative alpha and beta adrenergic blockers are given (if the carotid paraganglioma is secreting catecholamines) or less preferably angiographic embolization preoperatively. Radiotherapy, either alone or in conjunction with surgery, is
5 a second consideration and an area of some controversy. Unfortunately, due to location and/or size, paragangliomas, including carotid paragangliomas can be inoperable.

2. Pheochromocytomas

10 Pheochromocytomas occur in the adrenal medulla and cause clinical symptoms related to excess catecholamine production, including sudden high blood pressure (hypertension), headache, tachycardia, excessive sweating while at rest, the development of symptoms after suddenly rising from a bent-over position, and anxiety attacks. Abdominal imaging and 24
15 hour urine collection for catecholamines are usually sufficient for diagnosis. Catecholamine blockade with phenoxybenzamine and metyrosine generally ameliorates symptoms and is necessary to prevent hypertensive crisis during surgery, the current therapy of choice. Standard treatment is laparoscopic adrenalectomy, although partial adrenalectomy is often used
20 for familial forms of pheochromocytoma. Malignant (cancerous) pheochromocytomas are rare tumors.

Pheochromocytomas have been estimated to be present in approximately 0.3% of patients undergoing evaluation for secondary
25 causes of hypertension. Pheochromocytomas can be fatal if not diagnosed or if managed inappropriately. Autopsy series suggest that many pheochromocytomas are not clinically suspected and that the undiagnosed tumor is clearly associated with morbid consequences.

The progression of changes in the adrenal medulla can be from normal adrenal medulla to adrenal medullary hyperplasia (a generalized increase in the number of cells and size of the adrenal medulla without the specific development of a tumor) to a tumor of the adrenal medulla
5 (pheochromocytoma).

Treatment of a pheochromocytoma is surgical removal of one or both adrenal glands. Whether it is necessary to remove both adrenal glands will depend upon the extent of the disease. Patients who have had both
10 adrenal glands removed must take daily cortisol and aldosterone replacement. Cortisol is replaced by either hydrocortisone, cortisone or prednisone and must be taken daily. Aldosterone is replaced by oral daily fludrocortisone (Florineftm). Increased amounts of replacement
hydrocortisone or prednisone are required by such patients during periods
15 of stress, including fever, cold, influenza, surgical procedure or anesthesia.

3. Glomus Tumors

Glomus tumors (a type of paraganglioma) are generally benign neoplasms, also arising from neuroectodermal tissues, found in various
20 parts of the body. Glomus tumors are the most common benign tumors that arise within the temporal bone and fewer than five per cent of them become malignant and metastasize. Glomus tumors arise from glomus bodies distributed along parasympathetic nerves in the skull base, thorax and neck. There are typically three glomus bodies in each ear. The
25 glomus bodies are usually found accompanying Jacobsen's (CN IX) or Arnold's (CN X) nerve or in the adventitia of the jugular bulb. However, the physical location is usually the mucosa of the promontory (glomus tympanicums), or the jugular bulb (glomus jugulare).

The incidence of glomus jugulare tumors is about 1:1,300,000 population and the most striking bit of epidemiology is the predominant incidence in females with the female:male incidence ratio being at least 4:1. Catecholamine secreting (i.e. functional) tumors occur in about 1% to 3% of cases.

Glomus tumors have the potential to secrete catecholamines, similar to the adrenal medulla which also arises from neural crest tissue and can also secrete catecholamines. The neoplastic counterpart of a glomus tumor in the adrenal gland is the pheochromocytoma, and glomus tumors have been referred to as extra-adrenal pheochromocytoma. Catecholamine secreting glomus tumors can cause arrhythmia, excessive perspiration, headache, nausea and pallor.

Glomus tumors can arise in different regions of the skull base. When confined to the middle ear space, they are termed glomus tympanicum. When arising in the region of the jugular foramen, regardless of their extent, they are termed glomus jugulare. When they arise high in the neck, extending towards the jugular foramen, they are termed glomus vagale. When they arise in the area of the carotid bifurcation, they are called carotid body tumors. Other known sites of glomus tumors include the larynx, orbit, nose, and the aortic arch.

Glomus Jugulare tumors are the most common tumors of the middle ear. These tumors tend to be very vascular and are fed by branches of the external carotid artery. The symptoms of a glomus jugulare tumor include hearing loss with pulsatile ringing in the ear, dizziness, and sometimes ear pain. The patient can have a hearing loss due possibly to blockage of the middle ear, but also there can be a loss of hearing due to nerve injury from the tumor mass. Cranial nerve palsies of the nerves which control

swallowing, gagging, shoulder shrugging and tongue movement can all be part of the presentation of glomus jugulare tumors. When the tympanic membrane is examined a red/blue pulsatile mass can often be seen.

Symptoms are insidious in onset. Because of the location and the vascular nature of the tumors, a most common complaint is pulsatile tinnitus. It is believed that the tinnitus is secondary to mechanical impingement on the umbo in most cases. Other common symptoms are aural fullness, and (conductive) hearing loss.

Current therapy for a catecholamine secreting glomus tumor is irradiation and/or surgical ablation, preceded by administration of alpha and beta blockers. Treatment for glomus jugulare tumors includes administration of alpha and beta blockers. X-ray therapy can be used to improve symptoms even if the mass persists. It is also possible to embolize the tumor with materials which block its blood supply, however this procedure has associated problems with causing swelling of the tumor which can compress the brain stem and cerebellum as well as releasing the catecholamines from the cells which die when they lose their blood supply. Surgery can be carried out upon small tumors appropriately located. The complications of surgery for a glomus jugulare tumor are persistent leakage of cerebrospinal fluid from the ear and also palsy of one of the cranial nerves controlling face movement, sensation or hearing.

Even though the surgery may be successful glomus jugulare tumors are somewhat problematic because they have a high recurrence rate and may require multiple operations. Surgical ablation carries the risk of morbidity due mainly to iatrogenic cranial nerve deficits and CSF leaks. Lack of cranial nerve preservation is probably the most significant objection to surgical intervention because of the associated morbidity of lower cranial nerve deficits. Radiotherapy also has serious complications, including

osteoradionecrosis of the temporal bone, brain necrosis, pituitary-hypothalamic insufficiency, and secondary malignancy. Other postoperative complications include CSF leaks, aspiration syndromes, meningitis, pneumonia and wound infections.

5

Botulinum Toxin

The anaerobic, gram positive bacterium *Clostridium botulinum* produces a potent polypeptide neurotoxin, botulinum toxin, which causes a neuromuscular illness in humans and animals referred to as botulism. The spores of *Clostridium botulinum* are found in soil and can grow in improperly sterilized and sealed food containers of home based canneries, which are the cause of many of the cases of botulism. The effects of botulism typically appear 18 to 36 hours after eating the foodstuffs infected with a *Clostridium botulinum* culture or spores. The botulinum toxin can apparently pass unattenuated through the lining of the gut and attack peripheral motor neurons. Symptoms of botulinum toxin intoxication can progress from difficulty walking, swallowing, and speaking to paralysis of the respiratory muscles and death.

Botulinum toxin type A is the most lethal natural biological agent known to man. About 50 picograms of botulinum toxin (purified neurotoxin complex) type A¹ is a LD₅₀ in mice. One unit (U) of botulinum toxin is defined as the LD₅₀ upon intraperitoneal injection into female Swiss Webster mice weighing 18-20 grams each. Seven immunologically distinct botulinum neurotoxins have been characterized, these being respectively botulinum neurotoxin serotypes A, B, C₁, D, E, F and G each of which is distinguished by neutralization with type-specific antibodies. The different serotypes of botulinum toxin vary in the animal species that they affect and in the severity and duration of the paralysis they evoke. For example, it has

been determined that botulinum toxin type A is 500 times more potent, as measured by the rate of paralysis produced in the rat, than is botulinum toxin type B. Additionally, botulinum toxin type B has been determined to be non-toxic in primates at a dose of 480 U/kg which is about 12 times the
5 primate LD₅₀ for botulinum toxin type A. Botulinum toxin apparently binds with high affinity to cholinergic motor neurons, is translocated into the neuron and blocks the release of acetylcholine.

Botulinum toxins have been used in clinical settings for the treatment of
10 neuromuscular disorders characterized by hyperactive skeletal muscles. Botulinum toxin type A has been approved by the U.S. Food and Drug Administration for the treatment of blepharospasm, strabismus and hemifacial spasm. Non-type A botulinum toxin serotypes apparently have a lower potency and/or a shorter duration of activity as compared to
15 botulinum toxin type A. Clinical effects of peripheral intramuscular botulinum toxin type A are usually seen within one week of injection. The typical duration of symptomatic relief from a single intramuscular injection of botulinum toxin type A averages about three months.

20 Although all the botulinum toxins serotypes apparently inhibit release of the neurotransmitter acetylcholine at the neuromuscular junction, they do so by affecting different neurosecretory proteins and/or cleaving these proteins at different sites. For example, botulinum types A and E both cleave the 25 kiloDalton (kD) synaptosomal associated protein (SNAP-25),
25 but they target different amino acid sequences within this protein. Botulinum toxin types B, D, F and G act on vesicle-associated protein (VAMP, also called synaptobrevin), with each serotype cleaving the protein at a different site. Finally, botulinum toxin type C₁ has been shown to cleave both syntaxin and SNAP-25. These differences in mechanism of

¹Available from Allergan, Inc., of Irvine, California under the tradename BOTOX®.

action may affect the relative potency and/or duration of action of the various botulinum toxin serotypes.

The molecular weight of the botulinum toxin protein molecule, for all
5 seven of the known botulinum toxin serotypes, is about 150 kD.
Interestingly, the botulinum toxins are released by Clostridial bacterium as
complexes comprising the 150 kD botulinum toxin protein molecule along
with associated non-toxin proteins. Thus, the botulinum toxin type A
complex can be produced by Clostridial bacterium as 900 kD, 500 kD and
10 300 kD forms. Botulinum toxin types B and C₁ is apparently produced as
only a 500 kD complex. Botulinum toxin type D is produced as both 300 kD
and 500 kD complexes. Finally, botulinum toxin types E and F are
produced as only approximately 300 kD complexes. The complexes (i.e.
15 molecular weight greater than about 150 kD) are believed to contain a non-
toxin hemagglutinin protein and a non-toxin and non-toxic nonhemagglutinin
protein. These two non-toxin proteins (which along with the botulinum toxin
molecule comprise the relevant neurotoxin complex) may act to provide
stability against denaturation to the botulinum toxin molecule and protection
20 against digestive acids when toxin is ingested. Additionally, it is possible
that the larger (greater than about 150 kD molecular weight) botulinum
toxin complexes may result in a slower rate of diffusion of the botulinum
toxin away from a site of intramuscular injection of a botulinum toxin
complex.

25 *In vitro* studies have indicated that botulinum toxin inhibits potassium
cation induced release of both acetylcholine and norepinephrine from
primary cell cultures of brainstem tissue. Additionally, it has been reported
that botulinum toxin inhibits the evoked release of both glycine and
glutamate in primary cultures of spinal cord neurons and that in brain
30 synaptosome preparations botulinum toxin inhibits the release of each of

the neurotransmitters acetylcholine, dopamine, norepinephrine, CGRP and glutamate.

Botulinum toxin type A can be obtained by establishing and growing
5 cultures of *Clostridium botulinum* in a fermenter and then harvesting and
purifying the fermented mixture in accordance with known procedures. All
the botulinum toxin serotypes are initially synthesized as inactive single
chain proteins which must be cleaved or nicked by proteases to become
neuroactive. The bacterial strains that make botulinum toxin serotypes A
10 and G possess endogenous proteases and serotypes A and G can
therefore be recovered from bacterial cultures in predominantly their active
form. In contrast, botulinum toxin serotypes C₁, D and E are synthesized
by nonproteolytic strains and are therefore typically unactivated when
recovered from culture. Serotypes B and F are produced by both
15 proteolytic and nonproteolytic strains and therefore can be recovered in
either the active or inactive form. However, even the proteolytic strains that
produce, for example, the botulinum toxin type B serotype only cleave a
portion of the toxin produced. The exact proportion of nicked to unnicked
molecules depends on the length of incubation and the temperature of the
20 culture. Therefore, a certain percentage of any preparation of, for example,
the botulinum toxin type B toxin is likely to be inactive, possibly accounting
for the known significantly lower potency of botulinum toxin type B as
compared to botulinum toxin type A. The presence of inactive botulinum
toxin molecules in a clinical preparation will contribute to the overall protein
25 load of the preparation, which has been linked to increased antigenicity,
without contributing to its clinical efficacy. Additionally, it is known that
botulinum toxin type B has, upon intramuscular injection, a shorter duration
of activity and is also less potent than botulinum toxin type A at the same
dose level.

30

It has been reported that botulinum toxin type A has been used in clinical settings as follows:

- (1) about 75-125 units of BOTOX® per intramuscular injection (multiple muscles) to treat cervical dystonia;
- 5 (2) 5-10 units of BOTOX® per intramuscular injection to treat glabellar lines (brow furrows) (5 units injected intramuscularly into the procerus muscle and 10 units injected intramuscularly into each corrugator supercilii muscle);
- (3) about 30-80 units of BOTOX® to treat constipation by intrasphincter
10 injection of the puborectalis muscle;
- (4) about 1-5 units per muscle of intramuscularly injected BOTOX® to treat blepharospasm by injecting the lateral pre-tarsal orbicularis oculi muscle of the upper lid and the lateral pre-tarsal orbicularis oculi of the lower lid.
- 15 (5) to treat strabismus, extraocular muscles have been injected intramuscularly with between about 1-5 units of BOTOX®, the amount injected varying based upon both the size of the muscle to be injected and the extent of muscle paralysis desired (i.e. amount of diopter correction desired).
- 20 (6) to treat upper limb spasticity following stroke by intramuscular injections of BOTOX® into five different upper limb flexor muscles, as follows:
 - (a) flexor digitorum profundus: 7.5 U to 30 U
 - (b) flexor digitorum sublimus: 7.5 U to 30 U
 - 25 (c) flexor carpi ulnaris: 10 U to 40 U
 - (d) flexor carpi radialis: 15 U to 60 U
 - (e) biceps brachii: 50 U to 200 U. Each of the five indicated muscles has been injected at the same treatment session, so that the patient receives from 90 U to 360 U of upper limb flexor muscle BOTOX® by
30 intramuscular injection at each treatment session.

The success of botulinum toxin type A to treat a variety of clinical conditions has led to interest in other botulinum toxin serotypes. A study of two commercially available botulinum type A preparations (BOTOX[®] and Dysport[®]) and preparations of botulinum toxins type B and F (both obtained from Wako Chemicals, Japan) has been carried out to determine local muscle weakening efficacy, safety and antigenic potential. Botulinum toxin preparations were injected into the head of the right gastrocnemius muscle (0.5 to 200.0 units/kg) and muscle weakness was assessed using the mouse digit abduction scoring assay (DAS). ED₅₀ values were calculated from dose response curves. Additional mice were given intramuscular injections to determine LD₅₀ doses. The therapeutic index was calculated as LD₅₀/ED₅₀. Separate groups of mice received hind limb injections of BOTOX[®] (5.0 to 10.0 units/kg) or botulinum toxin type B (50.0 to 400.0 units/kg), and were tested for muscle weakness and increased water consumption, the later being a putative model for dry mouth. Antigenic potential was assessed by monthly intramuscular injections in rabbits (1.5 or 6.5 ng/kg for botulinum toxin type B or 0.15 ng/kg for BOTOX[®]). Peak muscle weakness and duration were dose related for all serotypes. DAS ED₅₀ values (units/kg) were as follows: BOTOX[®]: 6.7, Dysport[®]: 24.7, botulinum toxin type B: 27.0 to 244.0, botulinum toxin type F: 4.3. BOTOX[®] had a longer duration of action than botulinum toxin type B or botulinum toxin type F. Therapeutic index values were as follows: BOTOX[®]: 10.5, Dysport[®]: 6.3, botulinum toxin type B: 3.2. Water consumption was greater in mice injected with botulinum toxin type B than with BOTOX[®], although botulinum toxin type B was less effective at weakening muscles. After four months of injections 2 of 4 (where treated with 1.5 ng/kg) and 4 of 4 (where treated with 6.5 ng/kg) rabbits developed antibodies against botulinum toxin type B. In a separate study, 0 of 9 BOTOX[®] treated rabbits demonstrated

antibodies against botulinum toxin type A. DAS results indicate relative peak potencies of botulinum toxin type A being equal to botulinum toxin type F, and botulinum toxin type F being greater than botulinum toxin type B. With regard to duration of effect, botulinum toxin type A was greater
5 than botulinum toxin type B, and botulinum toxin type B duration of effect was greater than botulinum toxin type F. As shown by the therapeutic index values, the two commercial preparations of botulinum toxin type A (BOTOX® and Dysport®) are different. The increased water consumption behavior observed following hind limb injection of botulinum toxin type B
10 indicates that clinically significant amounts of this serotype entered the murine systemic circulation. The results also indicate that in order to achieve efficacy comparable to botulinum toxin type A, it is necessary to increase doses of the other serotypes examined. Increased dosage can comprise safety. Furthermore, in rabbits, type B was more antigenic than
15 as BOTOX®, possibly because of the higher protein load injected to achieve an effective dose of botulinum toxin type B.

Acetylcholine

Typically only a single type of small molecule neurotransmitter is
20 released by each type of neuron in the mammalian nervous system. The neurotransmitter acetylcholine is secreted by neurons in many areas of the brain, but specifically by the large pyramidal cells of the motor cortex, by several different neurons in the basal ganglia, by the motor neurons that innervate the skeletal muscles, by the preganglionic neurons of the
25 autonomic nervous system (both sympathetic and parasympathetic), by the postganglionic neurons of the parasympathetic nervous system, and by some of the postganglionic neurons of the sympathetic nervous system. Essentially, only the postganglionic sympathetic nerve fibers to the sweat glands, the piloerector muscles and a few blood vessels are cholinergic and
30 most of the postganglionic neurons of the sympathetic nervous system

secrete the neurotransmitter norepinephrine. In most instances acetylcholine has an excitatory effect. However, acetylcholine is known to have inhibitory effects at some of the peripheral parasympathetic nerve endings, such as inhibition of the heart by the vagus nerves.

5

The efferent signals of the autonomic nervous system are transmitted to the body through either the sympathetic nervous system or the parasympathetic nervous system. The preganglionic neurons of the sympathetic nervous system extend from preganglionic sympathetic neuron cell bodies located in the intermediolateral horn of the spinal cord. The preganglionic sympathetic nerve fibers, extending from the cell body, synapse with postganglionic neurons located in either a paravertebral sympathetic ganglion or in a prevertebral ganglion. Since, the preganglionic neurons of both the sympathetic and parasympathetic nervous system are cholinergic, application of acetylcholine to the ganglia will excite both sympathetic and parasympathetic postganglionic neurons.

Acetylcholine activates two types of receptors, muscarinic and nicotinic receptors. The muscarinic receptors are found in all effector cells stimulated by the postganglionic neurons of the parasympathetic nervous system, as well as in those stimulated by the postganglionic cholinergic neurons of the sympathetic nervous system. The nicotinic receptors are found in the synapses between the preganglionic and postganglionic neurons of both the sympathetic and parasympathetic. The nicotinic receptors are also present in many membranes of skeletal muscle fibers at the neuromuscular junction.

Acetylcholine is released from cholinergic neurons when small, clear, intracellular vesicles fuse with the presynaptic neuronal cell membrane. A wide variety of non-neuronal secretory cells, such as, adrenal medulla (as

well as the PC12 cell line) and pancreatic islet cells release catecholamines and insulin, respectively, from large dense-core vesicles. The PC12 cell line is a clone of rat pheochromocytoma cells extensively used as a tissue culture model for studies of sympathoadrenal development. Botulinum toxin inhibits the release of both types of compounds from both types of cells *in vitro*, permeabilized (as by electroporation) or by direct injection of the toxin into the denervated cell. Botulinum toxin is also known to block release of the neurotransmitter glutamate from cortical synaptosomes cell cultures.

10

What is needed therefore is an effective, non-surgical ablation, non-radiotherapy therapeutic method for treating neoplasms, such as hyperplastic and/or neoplastic, catecholamine secreting chromaffin cells, including paragangliomas, such as glomus tumors.

15

SUMMARY

The present invention meets this need and provides an effective, non-surgical ablation, non-radiotherapy therapeutic method for treating a various neoplasm, including paragangliomas, such as glomus tumors.

20

The present invention includes within its scope a method for treating a neoplasm by local administration of between about 10^{-3} U/kg and about 2000 U/kg of a botulinum toxin to the neoplasm, thereby treating the neoplasm by either reducing the size of the neoplasm and/or by reducing a secretion from the neoplasm.

25

A method according to the present invention can be carried out by direct injection of a botulinum toxin into the body of a neoplasm or by implantation of a botulinum toxin implant into or onto the body of the

30

neoplasm. A method within the scope of the present invention can be practiced to locally administer between about 10^{-3} U/kg and about 2000 U/kg of a botulinum toxin to a neoplasm. U/kg means units of a botulinum toxin per kilogram of total patient weight. The botulinum toxin can be one of the botulinum toxin types A, B, C₁, D, E, F and G, and is preferably a botulinum toxin type A because of the known clinical efficacy of botulinum toxin type A for a number of indications and because of its ready availability.

10 Preferably, the botulinum toxin is administered in an amount of between about 1 U and about 40,000 U (total units, not per kg of patient weight). At the higher dose ranges the amount of botulinum toxin administered (i.e. 40,000 units) can be administered in the form of a controlled release delivery system (i.e. an implant), whereby fractional amounts of the botulinum toxin depot (i.e. about 10 units of a botulinum toxin type A or about 500 units of a botulinum toxin type B) are released from the controlled release delivery system over a three to four month period (continuous release delivery system) or is released from the controlled release delivery system in a multiphasic manner in approximate three to four month repeating cycles (pulsatile release delivery system). Suitable controlled release delivery systems to use in the present invention for either the continuous or pulsatile intra or peri-neoplasm release of therapeutic amounts of a botulinum toxin are disclosed in co-pending applications serial number 09/587250 entitled "Neurotoxin Implant" and in the U.S. application 20 filed July 21, 2000 entitled "Botulinum Toxin Implant", serial number pending.

In a more preferred embodiment of the present invention, the amount of a botulinum toxin type A locally administered to the body of or to a site within the body of the neoplasm according to the present invention can be 30

an amount between about 10^{-3} U/kg and about 40 U/kg. Less than about 10^{-3} U/kg of a botulinum toxin type A is not expected to result in a significant therapeutic efficacy, while more than about 40 U/kg of a botulinum toxin type A can be expected to result in a toxic or near toxic dose of the toxin. With regard to a botulinum toxin type B, the amount of a botulinum toxin type B locally administered to the neoplasm according to the present invention can be an amount between about 10^{-3} U/kg and about 2000 U/kg. Less than about 10^{-3} U/kg of a botulinum toxin type B is not expected to result in a significant therapeutic efficacy, while more than about 2000 U/kg of a botulinum toxin type B can be expected to result in a toxic or near toxic dose of the type B toxin. It has been reported that about 2000 units/kg, intramuscular, of a commercially available botulinum toxin type B preparation approaches a primate lethal dose of type B botulinum toxin. Meyer K.E. et al, A
15 *Comparative Systemic Toxicity Study of Neurobloc in Adult and Juvenile Cynomolgus Monkeys*, Mov. Disord 15(Suppl 2);54;2000. With regard to the botulinum toxins types C, D, E, F and G, amounts for injection into a neoplasm can be determined on a patient by patient basis and are not expected to exceed the type B toxin dose range.

20

In a more preferred embodiment of the present invention, the amount of a type A botulinum toxin administered according to the disclosed methods is between about 10^{-2} U/kg and about 25 U/kg. Preferably, the amount of a type B botulinum toxin administered by a continuous release system during a given period is between about 10^{-2} U/kg and about 1000 U/kg, since it has been reported that less than about 1000 U/kg of type B botulinum toxin can be intramuscularly administered to a primate without systemic effect. *Ibid.* More preferably, the type A botulinum toxin is administered in an amount of between about 10^{-1} U/kg and about 15 U/kg. Most preferably,
25
30 the type A botulinum toxin is administered in an amount of between about 1

U/kg and about 10 U/kg. In many instances, an intraneoplastic administration of from about 1 units to less than about 100 units of a botulinum toxin type A, can provide effective and long lasting therapeutic relief, as set forth herein. More preferably, from about 5 units to about 75
5 units of a botulinum toxin, such as a botulinum toxin type A, can be used and most preferably, from about 5 units to about 50 units of a botulinum toxin type A, can be locally administered into a target neoplasm tissue with efficacious results. In a particularly preferred embodiment of the present invention from about 1 units to about 50 units of a botulinum toxin, such as
10 botulinum toxin type A, can be locally administered to a neoplasm target tissue with therapeutically effective results, as described herein.

A detailed method within the scope of the present invention can be carried out by local administration of between about 10^{-3} U/kg and about
15 2000 U/kg of a botulinum toxin type A to a neoplasm of a human patient, thereby reducing a secretion from the neoplasm. The secretion can be a catecholamine secretion.

The present invention also includes a method for treating a functional
20 neoplasm or functional chromaffin body by local administration of a neurotoxin to a neoplasm thereby reducing a catecholamine secretion from the neoplasm. As used herein "functional" means secreting a catecholamine, "local administration" means direct injection of the neurotoxin into or to the local area of the neoplasm and "neoplasm" (or
25 synonymously "tumor") means an abnormal tissue that grows more rapidly than normal and which may be either a benign tumor or a malignant tumor, (that is a cancer). Systemic routes of administration, such as oral and intravenous routes of administration, are excluded from the scope of the present invention. The functional neoplasm treated can be a
30 paraganglioma or a glomus tumor.

The botulinum toxin can be a modified botulinum toxin, that is the botulinum toxin can have at least one of its amino acids deleted, modified or replaced, as compared to a native botulinum toxin. Thus, the botulinum toxin can be a recombinant produced botulinum toxin or a derivative or fragment thereof.

A preferred method according to the present invention for treating a secretory neoplasm can have the step of local administration of a therapeutic amount of a botulinum toxin to a secretory neoplasm of a human patient, thereby reducing a secretion from the neoplasm. The secretion is a catecholamine secretion and the secretory tumor can be a functional paraganglioma. Furthermore, the functional paraganglioma can be, for example, a glomus tympanicum, a glomus jugulare, glomus vagale and a carotid body tumor.

The present invention also includes a method for improving patient function, the method comprising the step of administering a neurotoxin to a functional paraganglioma of a human patient, thereby improving patient function as determined by improvement in one or more of the factors of reduced pain, reduced time spent in bed, increased ambulation, healthier attitude and a more varied lifestyle.

A further method within the scope of the present invention for treating a secretion of a patient can have the step of administering to the patient an effective amount of a botulinum toxin in order to reduce the secretion, wherein the secretion is a catecholamine secretion. And the secretion can be an endocrine secretion from a chromaffin cell. Notably, the chromaffin cell can be a hyperplastic and/or hypertonic chromaffin cell and the secretion can be a cholinergic influenced secretion.

An additional method within the scope of the present invention can be a method for treating a cholinergic influenced, endocrine, catecholamine chromaffin cell secretion of a human patient by administering to a human
5 patient a therapeutically effective amount of botulinum toxin type A in order to reduce the secretion.

The present invention also includes a method for treating a gland by administering to a gland a botulinum toxin thereby reducing a secretory
10 activity of the gland, wherein the gland is a catecholamine secreting gland. The gland can be an excessively secreting gland and/or the gland can be influenced by the cholinergic nervous system. Additionally, the botulinum toxin can be administered by injection into the gland or into the local area of the gland.

15

Another preferred method within the scope of the present invention is a method for treating an excessively catecholamine secreting gland, the method comprising the step of injecting an excessively catecholamine secreting, cholinergic nervous system influenced gland or local gland area
20 of a human patient with a therapeutically effective amount of botulinum toxin type A in order to reduce the excessive catecholamine secretion. The invention also includes a method for treating an endocrine disorder, the method comprising the step of administering a neurotoxin to a mammal, thereby reducing an excessive secretion of an endocrine gland. Finally, the
25 invention encompasses a method for treating an adrenal disorder, the method comprising the step of administering a neurotoxin to an adrenal gland of a mammal, thereby reducing an excessive secretion of an adrenal gland.

The present invention also includes within its scope a method for treating a neoplasm, the method comprising the step of local administration of a botulinum toxin to a neoplasm or to the vicinity of the neoplasm, thereby causing a reduction in the size of the neoplasm. The neoplasm
5 can be a paraganglioma and the diameter of the neoplasm can be reduced by between about 20% and about 100% subsequent to the local administration of the botulinum toxin.

10

DESCRIPTION

The present invention is based upon the discovery that the size and/or a secretory activity of a wide variety of neoplasms can be reduced by treatment with a botulinum toxin. Additionally, excessively secreting
15 chromaffin cells and chromaffin bodies can be treated *in vivo* with a botulinum toxin to reduce the secretory activity. The target tissue is cholinergically innervated or susceptible to high toxin dosing such that the proteolytic light chain of the toxin is internalized by a cholinergic neuron which influences the activity of a neoplasm, such as a chromaffin cell
20 and/or by a target secretory chromaffin cell.

Thus, cholinergically innervated functional paragangliomas, pheochromocytomas and glomus tumors can be treated by local administration of a neurotoxin, such as a botulinum toxin. By local
25 administration it is meant that the neurotoxin is administered directly to, into, or to the vicinity of, the tumor or local tumor area to be treated. Local administration includes intratumor injection of a neurotoxin. Non-cancerous (benign), cancerous (malignant) hyperplastic and/or hypertonic catecholamine secreting tissues can be treated by a method within the
30 scope of the present invention. Nodular or diffuse hyperplasia which

precedes pheochromocytoma can also be treated by the present method. Hence, upon early diagnosis, botulinum injection can be used to reduce catecholamine secretion by hyperplastic, cholinergically innervated chromaffin cells.

5

I have discovered that a particular neurotoxin, botulinum toxin, can be used with dramatic ameliorative effect to treat a catecholamine secretory activity of paragangliomas, thereby significantly superseding current surgical and radiotherapy therapeutic oncological methods with regard to such neoplasms. Significantly, a single administration of the botulinum toxin can substantially reduces the tachycardia, headache, hypertension, and other catecholamine excess symptoms which can accompany a functional paraganglioma.

15

The route of administration and amount of botulinum toxin administered can vary widely according to the particular oncologic disorder being treated and various patient variables including size, weight, age, disease severity and responsiveness to therapy. Method for determining the appropriate route of administration and dosage are generally determined on a case by case basis by the attending physician. Such determinations are routine to one of ordinary skill in the art (see for example, *Harrison's Principles of Internal Medicine* (1997), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill). For example, to treat a tinnitus due to a middle ear glomus tumor, a solution of botulinum toxin type A complex can be endoscopically administered intramuscular directly to the tumor, thereby substantially avoiding entry of the toxin into the systemic circulation.

25

The specific dosage appropriate for administration is readily determined by one of ordinary skill in the art according to the factor discussed above. The dosage can also depend upon the size of the tumor to be treated or

30

denervated, and the commercial preparation of the toxin. Additionally, the estimates for appropriate dosages in humans can be extrapolated from determinations of the amounts of botulinum required for effective denervation of other non-neoplastic tissues. Thus, the amount of botulinum

5 A to be injected is proportional to the mass and level of activity of the neoplasm to be treated. Generally, between about 0.01 and 2000 units per kg of patient weight of a botulinum toxin, such as botulinum toxin type A, can be administered to effectively accomplish a toxin induced neoplastic atrophy upon administration of the neurotoxin at or to the vicinity of the

10 neoplasm. Less than about 0.01 U/kg of a botulinum toxin does not have a significant therapeutic effect upon a functional (i.e. catecholamine secreting) neoplasm, while more than about 2000 U/kg or 35 U/kg of a botulinum toxin B or A, respectively, approaches a toxic dose of the specified botulinum toxin. Careful placement of the injection needle and a

15 low volume of neurotoxin used prevents significant amounts of botulinum toxin from appearing systemically. A more preferred dose range to a functional paraganglioma is from about 0.01 U/kg to about 25 U/kg of a botulinum toxin, such as that formulated as BOTOX®. The actual amount of U/kg of a botulinum toxin to be administered depends upon factors such

20 as the extent (mass) and level of activity of the neoplasm to be treated and the administration route chosen. Botulinum toxin type A is a preferred botulinum toxin serotype for use in the methods of the present invention.

The main site of action of botulinum toxin is the neuromuscular junction

25 where the toxin binds rapidly and prevents the release of acetylcholine. Thus, while it is known that the botulinum toxins have a known binding affinity for cholinergic, pre-synaptic, peripheral motor neurons, I have discovered that the botulinum toxins can also bind to and translocate into a wide variety of non-neuronal secretory cells, where the toxin then acts, in

30 the known manner, as an endoprotease upon its respective secretory

vessel-membrane docking protein. Because of the lower affinity of the botulinum toxins for secretory cells, such as chromaffin cells, the toxin is preferably injected into secretory or glandular tissues to provide a high local concentration of the toxin. Thus, the present invention is applicable to the treatment of secretory, including catecholamine secreting, chromaffin cells and tumors located throughout the body, including secretory tumors with little or no cholinergic innervation.

Preferably, a neurotoxin used to practice a method within the scope of the present invention is a botulinum toxin, such as one of the serotype A, B, C, D, E, F or G botulinum toxins. Preferably, the botulinum toxin used is botulinum toxin type A, because of its high potency in humans, ready availability, and known use for the treatment of skeletal and smooth muscle disorders when locally administered by intramuscular injection.

15

A route for administration of a neurotoxin according to the present disclosed invention for treating a cancer can be selected based upon criteria such as the solubility characteristics of the neurotoxin toxin chosen as well as the amount of the neurotoxin to be administered. The amount of the neurotoxin administered can vary widely according to the particular disorder being treated, its severity and other various patient variables including size, weight, age, and responsiveness to therapy. For example, the extent of the neoplasm influenced is believed to be proportional to the volume of neurotoxin injected, while the quantity of the denervation is, for most dose ranges, believed to be proportional to the concentration of neurotoxin injected. Methods for determining the appropriate route of administration and dosage are generally determined on a case by case basis by the attending physician. Such determinations are routine to one of ordinary skill in the art (see for example, Harrison's Principles of Internal

Medicine (1997), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill).

The present invention includes within its scope the use of any
5 neurotoxin which has a long duration therapeutic effect when locally applied to a functioning paraganglioma of a patient. For example, neurotoxins made by any of the species of the toxin producing *Clostridium* bacteria, such as *Clostridium botulinum*, *Clostridium butyricum*, and *Clostridium beratti* can be used or adapted for use in the methods of the present
10 invention. Additionally, all of the botulinum serotypes A, B, C, D, E, F and G can be advantageously used in the practice of the present invention, although type A is the most preferred serotype, as explained above. Practice of the present invention can provide neoplastic atrophy and remission for 27 months or longer in humans.

15

It is known that catecholamine release from permeabilized adrenal medulla cells can be inhibited by a botulinum toxin. Additionally, it is known that release of insulin from permeabilized (as by electroporation) insulin secreting cells can be inhibited by a botulinum toxin. When *in vitro*, the cell
20 membranes of these non-nerve cells can be permeabilized to assist introduction of a botulinum toxin into the cell's cytosol due to the lack of cell surface receptors for a botulinum toxin. Thus, botulinum toxin type B apparently inhibits insulin secretion by cleaving synaptobrevin present in the insulin secreting cell line HIT-15. Boyd R.S., et al *The Effect of*
25 *Botulinum Neurotoxin-B On Insulin Release From a Beta Cell*, *Mov Disord* 10(3):376 (1995). It is the inventor's contention that a botulinum toxin can block the release of any vesicle mediated exocytosis from any secretory (i.e. neuronal, glandular, secretory, chromaffin) cell type, as long as the light chain of the botulinum toxin is translocated into the intracellular
30 medium. For example, the intracellular protein SNAP-25 is widely

distributed in both neuronal and non-neuronal secretory cells and botulinum toxin type A is an endopeptidase for which the specific substrate is SNAP-25. Thus, while cholinergic neurons have a high affinity acceptor for the botulinum and tetanus toxins (and are therefore more sensitive than other neurons and other cells to the inhibition of vesicle mediated exocytosis of secretory compounds), as the toxin concentration is raised, non-cholinergic sympathetic neurons, chromaffin cells and other cell types can take up a botulinum toxin and show reduced exocytosis.

Hence, by practice of the present disclosed invention, non-cholinergic nerve fibers as well as non or poorly innervated secretory neoplasms can be treated by use of an appropriately higher concentration of a botulinum toxin to bring about therapeutic atrophy of secretory neoplasms (i.e. treatment of functional (catecholamine secreting) paragangliomas) and hyperplastic chromaffin cells.

In the normal adrenal medulla, the catecholamine secretion rate is controlled by the activity of the nerves stimulating the chromaffin cells. Contrary to the general belief that the pheochromocytomas are not innervated and that the release of catecholamines from such tumors is not under nervous control, there is evidence for cholinergic innervation of such tumors. For example, electron microscopy has demonstrated a nerve with small synaptic vesicles in contact with cells containing catecholamine vesicles. Additionally, the sudden secretion of catecholamines from a pheochromocytomas into the circulation precipitated by an emotional upset, hypotension or hyperventilation points to a nervous system influence on the secretion. Furthermore, the tilting a patient with a pheochromocytoma from a horizontal to an upright position has been shown to cause an exaggerated increase in urinary norepinephrine not seen in subjects with such a tumor and this may effect result from (a) a mechanical effect (i.e.

compression of the catecholamine rich tumor) (b) reflex activation of the sympathetic system in which adrenergic system increased amounts of catecholamines may have accumulated in the nerve endings of a patient with a pheochromocytoma and/or (b) activation of existing
5 pheochromocytoma innervation.

Furthermore, a method within the scope of the present invention can provide improved patient function. "Improved patient function" can be defined as an improvement measured by factors such as a reduced pain,
10 reduced time spent in bed, increased ambulation, healthier attitude, more varied lifestyle and/or healing permitted by normal muscle tone. Improved patient function is synonymous with an improved quality of life (QOL). QOL can be assessed using, for example, the known SF-12 or SF-36 health survey scoring procedures. SF-36 assesses a patient's physical and
15 mental health in the eight domains of physical functioning, role limitations due to physical problems, social functioning, bodily pain, general mental health, role limitations due to emotional problems, vitality, and general health perceptions. Scores obtained can be compared to published values available for various general and patient populations.

20

As set forth above, I have discovered that a surprisingly effective and long lasting therapeutic effect can be achieved by local administration of a neurotoxin to a chromaffin body of a human patient. In its most preferred embodiment, the present invention is practiced by direct injection into the
25 neoplasm or to the local area of the neoplasm of botulinum toxin type A. It has been reported that at the neuroglandular junction, the chemical denervation effect of a botulinum toxin, such as botulinum toxin type A, has a considerably longer duration of action, i.e. 27 months vs. 3 months.

The present invention does include within its scope: (a) neurotoxin complex as well as pure neurotoxin obtained or processed by bacterial culturing, toxin extraction, concentration, preservation, freeze drying and/or reconstitution and; (b) modified or recombinant neurotoxin, that is

5 neurotoxin that has had one or more amino acids or amino acid sequences deliberately deleted, modified or replaced by known chemical/biochemical amino acid modification procedures or by use of known host cell/recombinant vector recombinant technologies, as well as derivatives or fragments of neurotoxins so made, and includes neurotoxins with one or

10 more attached targeting moieties for chromaffin and neoplasm cells types.

Botulinum toxins for use according to the present invention can be stored in lyophilized or vacuum dried form in containers under vacuum pressure. Prior to lyophilization the botulinum toxin can be combined with

15 pharmaceutically acceptable excipients, stabilizers and/or carriers, such as albumin. The lyophilized or vacuum dried material can be reconstituted with saline or water.

20

EXAMPLES

The following examples provide those of ordinary skill in the art with specific preferred methods within the scope of the present invention for carrying out the present invention and are not intended to limit the scope of

25 what the inventor regards as his invention.

One or two port endoscopy of the middle ear can be carried out. Thus, anatomical structures can be visualized by transmeatal or transtympanic rigid scopes of different angles and by a flexible scope in the eustachian

30 tube. Three endoscopic routes to the middle ear can be used, these

being: (1) transmeatal after raising a tympanomeatal flap, (2) transtympanic through a tympanic incision, and (3) the non-invasive through the preformed channel of the eustachian tube.

5

Example 1

Endoscopic Examination of A Middle Ear Glomus Tumor

A transtympanic endoscope can be used to view of the tympanic cavity. A flexible, steerable scope with an outside diameter of 0.8 mm (12,000
10 pixels; angle of view, 70°; total length, 650 mm; deflection angle, 90°; and length of deflectable part 25 mm) obtained from Micromed Co, Dornbim, Austria can be used for transtubar endoscopy. The patient's head can be positioned in 30° lateral decubitus. The transtubar scope can be introduced through a tubal catheter placed at the pharyngeal orifice of the eustachian
15 tube under endoscopic guidance (rigid 70° scope) through the contralateral nasal airway. After removing the rigid scope, the flexible steerable scope can be advanced into the middle ear through the tubal catheter. Successful advancement of the scope to the middle ear requires an adequate width of the tubal isthmus (mean, 1.0 mm wide and 2 mm high).

20

Transmeatal or transtympanic endoscopy can be performed using a rigid scope. Depending on the approach chosen, the outside diameter of the scope can be either 2.3 or 1.9 mm, with angles of 0°, 30°, or 70° (Karl Storz, Tuttlingen, and Aesculap). For the transmeatal approach, the
25 tympanic cavity can be opened by endoscopically raising a tympanomeatal flap so that the scope can enter the posterior part of the cavity below the incudostapedial joint. For the transtympanic approach, radial incisions can be made in the tympanic membrane either between the posterosuperior and the posteroinferior quadrant or in the anteroinferior quadrant,
30 depending on the region of interest. Images can be recorded on a digital

image recording device from S-VHS video sources (Digi-Still Unit and S-VHS Video Recorder; Sony, Vienna, Austria).

5 The field of view available depends on the angle of the scope (0°, 30°, or 70°). The 0° scopes can provide visualization only of the long process of the incus and the medial wall (labyrinthine wall). The 30° scopes can afford a larger view in all directions. The field of view can extend to the facial canal with the scope directed upward, to the round window niche with the scope directed downward, to the tympanic sinus with the scope
10 directed posteriorly, and to the cochleariform process with the scope directed anteriorly. The 70° scope can offer an even wider view of the tympanic cavity. With these, the tympanic chord and the aditus ad antrum can be seen above, the hypotympanum below, the lateral sinus and facial recess posteriorly, and the tympanic orifice of the tube anteriorly.

15

With a transtubal endoscope, the isthmus can be successfully negotiated and passage aided by subtly maneuvering and turning the scope tip. Once the steerable scope has reached the protympanum, it can be advanced along 2 alternative routes: (1) above the tensor tendon into the
20 epitympanum and then along the tegmen to the mastoid antrum; or (2) below the tensor tendon into the mesotympanum toward the incudostapedial joint and then either (a) medial to the incus and above the stapes into the aditus ad antrum or (b) lateral to the incus toward the tympanic chord or (c) below the stapes toward the lateral sinus. As the
25 scope is advanced through the mesotympanum, it passes the entire tympanic membrane, which forms the lateral wall and can be inspected in its entire extension. Along the routes described, the flexible scope can be easily maneuvered past the ossicles without injuring them.

In each of the following examples, the specific amount of BOTOX® administered depends upon a variety of factors to be weighed and considered within the discretion of the attending physician and in each of the examples insignificant amounts of botulinum toxin appear systemically
5 with no significant side effects.

Example 2

Treatment of Catecholamine Secreting Glomus Tumor

10 A female patient, aged 58 presents with tachycardia, headache and elevated urine catecholamines metabolites. Adrenal function is normal. A benign, functional, middle ear glomus tumor is identified and is treated by endoscopic injection of from 10 unit to 100 units of BOTOX® into the tumor mass. Within 1-7 days serum catecholamines return to normal and remain
15 so for the ensuing 2 to 24 months.

Other glomus tumors which have arisen from glomus bodies distributed along parasympathetic nerves in the skull base, thorax and neck can be likewise treated.

20

Example 3

Treatment of Catecholamine Secreting Carotid Paraganglioma

25 A 44 year old male patient with a neck mass is examined and a diagnosis of carotid paraganglioma is made. Grossly the carotid paraganglioma is dark, tan to purple in color and is fairly well circumscribed with a very thin fibrous capsule, presented as a non-tender neck mass located just anterior to the sternocleidomastoid muscle at the level of the
30 hyoid. The patient shows symptoms associated with catecholamine production, such as fluctuating hypertension, blushing and palpitations. Screening for urinary metanephrines and serum catecholamines is positive.

Perioperative alpha and beta adrenergic blockers are given. The approach is transcervical and from 10 unit to 150 units of BOTOX® is injected into the mass of the tumor which is in proximity to or innervated by the glossopharyngeal nerve. Within 1-7 days serum catecholamines return to
5 normal and remain so for the ensuing 2 to 27 months.

Example 4
Treatment of Hyperplasic Adrenal Medulla

10 A 62 year old female is admitted with symptoms of excessive catecholamine production, including tachycardia and hypertension. The patient abstains from bananas, vanilla, coffee, tea, cocoa, chocolate, cola beverages, or medications such as tranquilizers and nose sprays for colds for 2 days. Measurement of adrenalin and noradrenalin breakdown
15 products in blood and a 24-hour collection of urine confirms the existence of an excessive catecholamine secretion. A computerized tomographic scan (CT or MRI to provide a 3-dimensional picture of the adrenal gland), or a nuclear medicine scan is carried out to attempt determination of the location and size of the tumor. Biopsy reveals a precancerous, hyperplasic
20 adrenal medulla. From 10 to 150 units of BOTOX® is injected endoscopically directly into the adrenal medulla. Within 1-7 days serum catecholamines return to normal and remain so for the ensuing 2 to 24 months.

25 Example 5
Treatment of a Neoplasm With Botulinum Toxin Type A

A 24 year old female presents with a history of tachycardia and hypertension. A diagnosis of paraganglioma is made. Under radiographic
30 guidance 30 units of BOTOX® is injected directly into the tumor. Within 1 to 7 days the tachycardia and hypertension has been substantially alleviated

and the patient remains asymptomatic thereafter. Radiography and at 3 months post injection fails to reveal any evidence of the neoplasm.

5

Example 6

Treatment of a Neoplasm With Botulinum Toxin Type B

A 42 year old female presents with a history of tachycardia and hypertension. A diagnosis of paraganglioma is made. Under radiographic
10 guidance 1500 units of a botulinum type B preparation is injected directly into the tumor. Within 1 to 7 days the tachycardia and hypertension has been substantially alleviated and the patient remains asymptomatic thereafter. Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.

15

Example 7

Treatment of a Neoplasm With Botulinum Toxin Type C

A 58 year old female is diagnosed with a paraganglioma. Between
20 about 10^{-3} U/kg and about 35 U/kg of a botulinum toxin type C preparation (for example between about 10 units and about 10,000 units of a botulinum type C preparation) is injected directly into the tumor. Within 1 to 7 days the tachycardia and hypertensive symptoms are been substantially alleviated and the patient remains asymptomatic. Radiography and biopsy
25 at 3 months post injection fails to reveal any evidence of the neoplasm.

Example 8

Treatment of a Neoplasm With Botulinum Toxin Type D

30 A 56 year old obese female is diagnosed with paraganglioma. Between about 10^{-3} U/kg and about 35 U/kg of a botulinum toxin type D

preparation (for example between about 10 units and about 10,000 units of a botulinum type D preparation) is injected directly into the tumor. Within 1 to 7 days the tachycardia and hypertensive symptoms have been substantially alleviated and the patient remains asymptomatic.

- 5 Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.

Example 9

Treatment of a Neoplasm With Botulinum Toxin Type E

10

A 61 year old female is diagnosed with paraganglioma. Between about 10^{-3} U/kg and about 35 U/kg of a botulinum toxin type E preparation (for example between about 10 units and about 10,000 units of a botulinum type E preparation) is injected directly into the tumor. Within 1 to 7 days
15 the tachycardia and hypertensive symptoms have been substantially alleviated and the patient remains asymptomatic. Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.

20

Example 10

Treatment of a Neoplasm With Botulinum Toxin Type F

A 52 year old male is diagnosed with paraganglioma. Between about 10^{-3} U/kg and about 35 U/kg of a botulinum toxin type F preparation (for
25 example between about 10 units and about 10,000 units of a botulinum type F preparation) is injected directly into the tumor. Within 1 to 7 days the tachycardia and hypertensive symptoms have been substantially alleviated and the patient remains asymptomatic. Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.

30

Example 11

Treatment of a Neoplasm With Botulinum Toxin Type G

A 14 year old male is diagnosed with paraganglioma. Between about 10^{-3} U/kg and about 35 U/kg of a botulinum toxin type G preparation (for example between about 10 units and about 10,000 units of a botulinum type G preparation) is injected directly into the tumor. Within 1 to 7 days the tachycardia and hypertensive symptoms have been substantially alleviated and the patient remains asymptomatic. Radiography and biopsy at 3 months post injection fails to reveal any evidence of the neoplasm.

10

Methods according to the invention disclosed herein has many advantages, including the following:

(1) the invention renders unnecessary many surgical procedures for effective treatment of functioning chromaffin bodies, including hyperplastic, hypertonic and neoplastic catecholamine secreting tissues.

(2) systemic drug effects can be avoided by direct local application of a neurotoxin according to the present invention

20

(3) the ameliorative effects of the present invention can persists for two years or longer from a single local administration of a neurotoxin as set forth herein.

Although the present invention has been described in detail with regard to certain preferred methods, other embodiments, versions, and modifications within the scope of the present invention are possible. For example, a wide variety of neurotoxins can be effectively used in the methods of the present invention. Additionally, the present invention includes local otic administration methods wherein two or more

25
30

neurotoxins, such as two or more botulinum toxins, are administered concurrently or consecutively. For example, botulinum toxin type A can be administered until a loss of clinical response or neutralizing antibodies develop, followed by administration of botulinum toxin type E. Alternately, a
5 combination of any two or more of the botulinum serotypes A-G can be locally administered to control the onset and duration of the desired therapeutic result. Furthermore, non-neurotoxin compounds can be administered prior to, concurrently with or subsequent to administration of the neurotoxin to provide adjunct effect such as enhanced or a more rapid
10 onset of denervation before the neurotoxin, such as a botulinum toxin, begins to exert its therapeutic effect.

My invention also includes within its scope the use of a neurotoxin, such as a botulinum toxin, in the preparation of a medicament for the treatment
15 of a functioning chromaffin body disorder by local administration of the neurotoxin.

Accordingly, the spirit and scope of the following claims should not be limited to the descriptions of the preferred embodiments set forth above.

20

I claim:

1. A method for treating a neoplasm, the method comprising the step of
5 local administration of between about 10^{-3} U/kg and about 2000 U/kg of a
botulinum toxin to a neoplasm, thereby treating the neoplasm.
2. The method of claim 1, wherein the botulinum toxin is administered
10 in an amount of between about 1 U and about 40,000 U.
3. The method of claim 1, wherein the botulinum toxin is administered
in an amount of between about 10^{-3} U/kg and about 35 U/kg.
15
4. The method of claim 1, wherein the botulinum toxin is administered
in an amount of between about 10^{-2} U/kg and about 25 U/kg.
20
5. The method of claim 1, wherein the botulinum toxin is administered
in an amount of between about 10^{-2} U/kg and about 15 U/kg.
- 25 6. The method of claim 1, wherein the botulinum toxin is administered
in an amount of between about 1 U/kg and about 10 U/kg.

7. The method of claim 1, wherein local administration of the botulinum toxin is carried out by implantation of a botulinum toxin implant into or onto the body of the neoplasm.

5

8. The method of claim 1, wherein the neoplasm is a paraganglioma.

9. The method of claim 1, wherein the neoplasm is a glomus tumor.

10

10. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F and G.

15

11. The method of claim 1, wherein the neurotoxin is botulinum toxin type A.

20

12. The method of claim 1, wherein the botulinum toxin is locally administered by direct injection of the botulinum toxin into the neoplasm.

25

13. A method for treating a neoplasm, the method comprising the step of local administration of between about 10^{-3} U/kg and about 2000 U/kg of a botulinum toxin type A to a neoplasm of a human patient, thereby reducing a secretion from the neoplasm.

14. The method of claim 13, wherein the secretion is a catecholamine secretion.

5 15. The method of claim 13, wherein the neoplasm is a paraganglioma.

16. A method for treating a neoplasm, the method comprising the step
of local administration of a botulinum toxin to a neoplasm or to the vicinity
10 of the neoplasm, thereby causing a reduction in the size of the neoplasm.

17. The method of claim 16, wherein the neoplasm is a paraganglioma.

15

18. The method of claim 13, wherein the diameter of the neoplasm is
reduced by between about 20% and about 100% subsequent to the local
administration of the botulinum toxin.

20

19. A method for treating a neoplasm, the method comprising the step
of local administration of a therapeutic amount of a botulinum toxin to a
neoplasm or to the vicinity of the neoplasm, thereby causing a reduction in
the diameter of the neoplasm of between about 20% and about 100%.

25

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/22885

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K38/48 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | WO 95 17904 A (ALLERGAN INC) 6 July 1995 (1995-07-06) example 5 | 1-19 |
| P,X | WO 01 41790 A (DONOVAN STEPHEN ; ALLERGAN SALES INC (US)) 14 June 2001 (2001-06-14) the whole document | |
| A | MUNCHAU A & BHATIA K P: "Uses of botulinum toxin injection in medicine today." BRITISH MEDICAL JOURNAL, vol. 319, no. 7228, 15 January 2000 (2000-01-15), pages 161-165, XP002182213 -/- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

8 November 2001

Date of mailing of the international search report

19/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Teyssier, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/22885

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | SCHANTZ E J & JOHNSON E A: "Properties and use of botulinum toxin and other microbial neurotoxins in medicine" MICROBIOLOGICAL REVIEWS, vol. 56, no. 1, 1 March 1992 (1992-03-01), pages 80-99, XP000569909 | |
| A | US 5 466 672 A (KUSHNARYOV VLADIMIR M ET AL) 14 November 1995 (1995-11-14) | |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/22885

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9517904 | A | 06-07-1995 | AU 688452 B2 | 12-03-1998 |
| | | | AU 1516295 A | 17-07-1995 |
| | | | AU 712502 B2 | 11-11-1999 |
| | | | AU 7010598 A | 30-07-1998 |
| | | | CA 2180011 A1 | 06-07-1995 |
| | | | DE 69427869 D1 | 06-09-2001 |
| | | | EP 1072270 A2 | 31-01-2001 |
| | | | EP 1103267 A1 | 30-05-2001 |
| | | | EP 1147775 A2 | 24-10-2001 |
| | | | EP 1147776 A2 | 24-10-2001 |
| | | | EP 0737074 A1 | 16-10-1996 |
| | | | EP 0770395 A1 | 02-05-1997 |
| | | | EP 1010431 A2 | 21-06-2000 |
| | | | EP 1005867 A2 | 07-06-2000 |
| | | | ES 2159624 T3 | 16-10-2001 |
| | | | JP 9507234 T | 22-07-1997 |
| | | | WO 9517904 A2 | 06-07-1995 |
| | | | US 6290961 B1 | 18-09-2001 |
| | | | US 2001018415 A1 | 30-08-2001 |
| WO 0141790 | A | 14-06-2001 | US 6139845 A | 31-10-2000 |
| | | | AU 7085200 A | 18-06-2001 |
| | | | WO 0141790 A1 | 14-06-2001 |
| US 5466672 | A | 14-11-1995 | AU 6555994 A | 08-11-1994 |
| | | | WO 9424155 A1 | 27-10-1994 |
| | | | AU 688763 B2 | 19-03-1998 |
| | | | AU 6653894 A | 04-07-1994 |
| | | | CA 2150935 A1 | 23-06-1994 |
| | | | EP 0671902 A1 | 20-09-1995 |
| | | | WO 9413264 A1 | 23-06-1994 |
| | | | WO 9612802 A1 | 02-05-1996 |
| | | | US 5601823 A | 11-02-1997 |
| | | | US 5599539 A | 04-02-1997 |
| | | | US 5919665 A | 06-07-1999 |
| | | | US 5762934 A | 09-06-1998 |
| | | | US 5814477 A | 29-09-1998 |
| | | | US 5719267 A | 17-02-1998 |
| | | | US 5736139 A | 07-04-1998 |
| | | | US 6290960 B1 | 18-09-2001 |

